Mereo On The Move With Strong COPD Data And US Listing Plan

The UK firm, boosted by promising data for acumapimod for acute exacerbations of COPD, is seeking to conduct an initial public offering in the US.

Businessman
America calling: The UK's Mereo is looking at a US listing • Source: Shutterstock

Mereo BioPharma Group PLC.'s model of acquiring then developing assets from big pharma looks to be paying dividends again, highlighted by impressive data on its chronic obstructive pulmonary disease (COPD) drug acumapimod, bought off Novartis AG, and plans to list in the US.

Last week, the UK company announced positive top-line results from a Phase II trial with acumapimod in acute exacerbations of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category